Article
Medicine, General & Internal
Ran Pan, Xiaolun Wang, Min Shu, Jaydeep Das, Manik Kalra, Zhidong Wang
Summary: The efficacy of SEC in the treatment of patients with moderate-to-severe plaque psoriasis is well demonstrated through NMA.
CHINESE MEDICAL JOURNAL
(2022)
Article
Medicine, General & Internal
Kristian Reich, Richard B. Warren, Mark Lebwohl, Melinda Gooderham, Bruce Strober, Richard G. Langley, Carle Paul, Dirk De Cuyper, Veerle Vanvoorden, Cynthia Madden, Christopher Cioffi, Luke Peterson, Andrew Blauvelt
Summary: In patients with moderate-to-severe psoriasis, treatment with bimekizumab resulted in greater skin clearance than treatment with secukinumab over 16 and 48 weeks but was associated with oral candidiasis. Longer and larger trials are needed to determine comparative effects and risks of interleukin-17 inhibitors in psoriasis.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Dermatology
Zenas Z. N. Yiu, Gabrielle Becher, Brian Kirby, Philip Laws, Nick J. Reynolds, Catherine H. Smith, Richard B. Warren, Christopher E. M. Griffiths
Summary: The results of this cohort study suggest that guselkumab had the highest drug survival among the included biologics for treating psoriasis in terms of effectiveness, and guselkumab had the highest drug survival for safety compared with other biologics except ustekinumab.
Article
Dermatology
Luca Mastorino, Paolo Dapavo, Sara Susca, Caterina Cariti, Niccolo Siliquini, Anna Verrone, Elena Stroppiana, Michela Ortoncelli, Pietro Quaglino, Simone Ribero
Summary: IL-23 inhibitors showed the best performance in drug survival for patients with psoriasis. IL-17 inhibitors were more effective in the short-term, but anti-IL-23 showed better long-term effectiveness. Male patients and those treated with risankizumab and guselkumab had a lower probability of drug interruption.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2023)
Article
Medicine, General & Internal
R. B. Warren, A. Blauvelt, J. Bagel, K. A. Papp, P. Yamauchi, A. Armstrong, R. G. Langley, V. Vanvoorden, D. De Cuyper, C. Cioffi, L. Peterson, N. Cross, K. Reich
Summary: The study found that bimekizumab was both noninferior and superior to adalimumab in reducing symptoms and signs of moderate-to-severe plaque psoriasis at week 16, but was associated with a higher frequency of oral candidiasis and diarrhea. Longer and larger trials are needed to further evaluate the efficacy and safety of bimekizumab compared to other agents in treating plaque psoriasis.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Dermatology
Timothy Fitzgerald, Maryia Zhdanava, Dominic Pilon, Aditi Shah, Annalise Hilts, Patrick Lefebvre, Steven R. R. Feldman
Summary: This study described the persistence and remission rates of patients with psoriasis initiated on current biologics. The results showed that patients using guselkumab had longer persistence and higher remission rates compared to other biologics.
DERMATOLOGY AND THERAPY
(2023)
Article
Dermatology
K. Reich, J. Sullivan, P. Arenberger, S. Jazayeri, U. Mrowietz, M. Augustin, B. Elewski, R. You, P. Regnault, J. A. Frueh
Summary: Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2 center dot 5 years in nail psoriasis, with significant sustained quality-of-life improvements and a favorable safety profile. No new safety findings were observed, indicating the long-term safety of Secukinumab in treating nail psoriasis.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
N. Onsun, B. Gunes, G. Kaya, Guckan B. Isik, Yabaci A. Tak
Summary: This study evaluates the long-term survival rates of adalimumab and infliximab based on real-life clinical data, and finds that the efficacy of these two drugs decreases over time.
Article
Pharmacology & Pharmacy
Theodora Simopoulou, Sotirios G. Tsiogkas, Efterpi Zafiriou, Dimitrios P. Bogdanos
Summary: In recent years, there has been significant interest in the role of interleukin-17 (IL-17) in promoting proinflammatory immune responses. IL-17, due to its inhibitory effect on immuno-regulation and stimulatory action on inflammation, has become a target for drug development. This review discusses the recent developments in IL-17 inhibitors, such as secukinumab, ixekizumab, bimekizumab, and brodalumab, for the treatment of psoriasis and psoriatic arthritis.
Article
Dermatology
Maria C. C. Schneeweiss, Timothy J. J. Savage, Richard Wyss, Yinzhu Jin, Katharina Schoder, Joseph F. F. Merola, Robert Sidbury, Theresa Oduol, Sebastian Schneeweiss, Robert J. J. Glynn
Summary: The study aimed to estimate the 6-month infection rate among children with psoriasis who started treatment with ustekinumab, etanercept, or methotrexate.
Article
Multidisciplinary Sciences
T. Graier, W. Weger, C. Jonak, P. Sator, C. Zikeli, K. Prillinger, C. Sassmann, B. Gruber, W. Saxinger, G. Ratzinger, C. Painsi, A. Mlynek, N. Haering, B. Sadoghi, H. Trattner, R. Muellegger, F. Quehenberger, W. Salmhofer, Peter Wolf
Summary: In this study, the effectiveness and safety of IL-23p19 inhibitors in real-world patients were analyzed. Few differences in PASI improvement were detected among biologic-naive and biologic-non-naive patients treated with different IL-23p19 inhibitors after correction for previous biologic exposure. IL-23p19 inhibitors represent a promising treatment alternative for patients who have not responded to previous biologics.
SCIENTIFIC REPORTS
(2022)
Article
Dermatology
Georgios Kokolakis, Richard B. Warren, Bruce Strober, Andrew Blauvelt, Luis Puig, Akimichi Morita, Melinda Gooderham, Andreas Koerber, Veerle Vanvoorden, Maggie Wang, Dirk de Cuyper, Cynthia Madden, Natalie Nunez Gomez, Mark Lebwohl
Summary: This study evaluated the efficacy and safety of switching to bimekizumab from adalimumab, ustekinumab, and secukinumab. The results showed rapid and durable improvements in clinical responses among nonresponders who switched to bimekizumab. Furthermore, the majority of patients who responded well to previous treatments maintained or improved their response after switching to bimekizumab. Overall, switching to bimekizumab was found to be highly effective and well tolerated for psoriasis patients.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
L. S. van der Schoot, J. J. Janssen, M. T. Bastiaens, A. de Boer-Brand, C. Christiaansen-Smit, D. N. H. Enomoto, R. Hovingh, R. A. Tupker, M. M. B. Seyger, L. M. Verhoef, J. M. P. A. van den Reek, E. M. G. J. de Jong
Summary: Implementation of protocolized biologic dose reduction can increase patient uptake of treatment, with additional staff support, extra consultation time, education for healthcare providers and patients, and effective tools such as a feasible protocol leading to more patients on biologic dose reduction.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Article
Dermatology
Gayle van der Kraaij, Celine Busard, Juul van den Reek, Stef Menting, Annelie Musters, Barbara Hutten, Menno de Rie, Wouter Ouwerkerk, Sun-Jine Van Bezooijen, Errol Prens, Theo Rispens, Annick de Vries, Elke de Jong, Wim de Kort, Jo Lambert, Martijn van Doorn, Phyllis Spuls
Summary: This study evaluated the efficacy, safety, and pharmacokinetic profile of adalimumab combined with methotrexate in the treatment of chronic plaque psoriasis. The results showed that combination therapy resulted in fewer patients showing antidrug antibodies and a trend towards improved treatment response.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Review
Dermatology
Mette Gyldenlove, Farzad Alinaghi, Claus Zachariae, Lone Skov, Alexander Egeberg
Summary: The evidence for combination therapy with apremilast and biologics is limited and mainly based on retrospective studies. Based on available data, apremilast may be an effective and safe add-on treatment to biologic therapy, but further clinical research is needed.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2022)
Article
Immunology
Katie N. Truitt, Tiffany Brown, Ji Young Lee, Jeffrey A. Linder
Summary: The proportion of sinusitis visits meeting antibiotic prescribing criteria is unknown. In a study of 425 sinusitis visits, 50% met antibiotic prescribing criteria, with no significant difference in antibiotic prescribing between visits that did and did not meet the criteria.
CLINICAL INFECTIOUS DISEASES
(2021)
Editorial Material
Immunology
Jeffrey A. Linder
CLINICAL INFECTIOUS DISEASES
(2021)
Letter
Health Care Sciences & Services
Kao-Ping Chua, Jeffrey A. Linder
JOURNAL OF GENERAL INTERNAL MEDICINE
(2021)
Editorial Material
Medicine, General & Internal
Craig R. Fox, Jason N. Doctor, Noah J. Goldstein, Daniella Meeker, Stephen D. Persel, Jeffrey A. Linder
BMJ-BRITISH MEDICAL JOURNAL
(2020)
Review
Medicine, General & Internal
David T. Liss, Toshiko Uchida, Cheryl L. Wilkes, Ankitha Radakrishnan, Jeffrey A. Linder
Summary: General health checks are often not associated with decreased mortality or cardiovascular events, but are linked to increased detection and treatment of chronic diseases, control of risk factors, uptake of preventive services, and improvements in patient-reported outcomes. Primary care teams can reasonably offer general health checks, especially to high-risk groups who are overdue for preventive services, have uncontrolled risk factors, low self-rated health, or inadequate access to primary care.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Review
Pharmacology & Pharmacy
Alexandra R. Richards, Jeffrey A. Linder
Summary: Behavioral economics identifies environmental, psychological, social, and emotional factors that influence inappropriate antibiotic prescribing in ambulatory settings. Approaches informed by behavioral economics such as precommitment, justification alerts, and peer comparison have shown effectiveness in reducing inappropriate antibiotic prescribing rates among clinicians. Future directions in applying behavioral economics to this issue include attention to design, intervention effectiveness and durability, making harms salient, involving participants in intervention development, considering patient satisfaction, and implementing patient-facing nudges. Additionally, the COVID pandemic may further aid in improving ambulatory antibiotic prescribing due to changes in cognitive frames around respiratory symptoms and antibiotic use.
CLINICAL THERAPEUTICS
(2021)
Article
Public, Environmental & Occupational Health
Dharmesh Patel, Teresa Ng, Lubna S. Madani, Stephen D. Persell, Mark Greg, Phillip E. Roemer, Sonali K. Oberoi, Jeffrey A. Linder
Summary: This study aimed to develop and implement antibiotic stewardship activities targeting non-antibiotic-appropriate acute respiratory tract infections (ARIs) to reduce overall antibiotic prescribing and maintain patient satisfaction. Results showed that the antibiotic prescribing rate significantly decreased under the stewardship activities, and patient satisfaction with the healthcare services also improved.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
(2023)
Article
Health Care Sciences & Services
Laura M. Perry, Victoria Morken, John D. Peipert, Betina Yanez, Sofia F. Garcia, Cynthia Barnard, Lisa R. Hirschhorn, Jeffrey A. Linder, Neil Jordan, Ronald T. Ackermann, Alexandra Harris, Sheetal Kircher, Nisha Mohindra, Vikram Aggarwal, Rebecca Frazier, Ava Coughlin, Katy Bedjeti, Melissa Weitzel, Eugene C. Nelson, Glyn Elwyn, Aricca D. Van Citters, Mary O'Connor, David Cella
Summary: This study aims to co-design a dashboard that integrates patient-reported outcomes with other clinical data and evaluate its association with improved shared decision-making and disease management outcomes through a demonstration trial. By collaborating to develop the dashboard and implementing it for clinical testing, researchers will work with clinic staff to assess the impact. Results will be disseminated in at least one manuscript per study objective.
JMIR RESEARCH PROTOCOLS
(2022)
Article
Infectious Diseases
Adriana Guzman, Tiffany Brown, Ji Young Lee, Michael A. Fischer, Mark W. Friedberg, Kao-Ping Chua, Jeffrey A. Linder
Summary: This study assessed the impact of different durations on the appropriateness of antibiotic prescribing. The study found that the proportion of appropriate antibiotics remained stable across different durations, while the proportion of potentially appropriate antibiotics increased with longer durations. Inappropriate antibiotics and antibiotics not associated with any diagnosis decreased accordingly.
Editorial Material
Immunology
Julia E. Szymczak, Jeffrey A. Linder
OPEN FORUM INFECTIOUS DISEASES
(2023)
Article
Multidisciplinary Sciences
Tiffany Brown, Ji Young Lee, Adriana Guzman, Michael A. Fischer, Mark W. Friedberg, Kao-Ping Chua, Jeffrey A. Linder
Summary: This retrospective cohort study examines ambulatory antibiotic prescribing in the United States and finds that a significant proportion of antibiotics are prescribed without in-person visits. Non-in-person encounters, such as telephone consultations and refills, account for 19% of antibiotic prescriptions. These prescriptions are more likely to be for chronic use, less likely to be associated with appropriate diagnoses, and more likely to be associated with no diagnosis.
Article
Hematology
Karlyn A. Martin, Rebecca Molsberry, Sadiya S. Khan, Jeffrey A. Linder, Kenzie A. Cameron, Al Benson
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS
(2020)
Meeting Abstract
Health Care Sciences & Services
Theresa A. Rowe, Ji Young Lee, Tiffany Brown, Yaw A. Peprah, Jeffrey A. Linder, Mark W. Friedberg, Stephen Persell
JOURNAL OF GENERAL INTERNAL MEDICINE
(2020)
Meeting Abstract
Health Care Sciences & Services
Tiffany Brown, Ji Young Lee, Stephen Persell, Daniella Meeker, Tara Knight, Jason N. Doctor, Jeffrey A. Linder
JOURNAL OF GENERAL INTERNAL MEDICINE
(2020)
Meeting Abstract
Health Care Sciences & Services
Tiffany Brown, Stephen Persell, Ji Young Lee, Jeffrey A. Linder, Mark W. Friedberg
JOURNAL OF GENERAL INTERNAL MEDICINE
(2020)